ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1215

Interferon Signature Genes Are Differentially Expressed Between Microscopic Polyangiitis and Systemic Lupus Erythematosus Peripheral Blood Transcriptomes

Aya Kawasaki1, Daisuke Tsukui2, Yuya Kondo3, Yoshitaka Kimura2, Kurumi Asako2, Hiroshi Furukawa1, Hajime Kono2, Takayuki Sumida4 and Naoyuki Tsuchiya1, 1Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 3Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, 4Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ANCA, SLE and interferons

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Genetics, Genomics and Proteomics - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Interferon (IFN) signature has been established in the peripheral blood of the patients with systemic lupus erythematosus (SLE) by transcriptome analyses, indicating a role of the IFN pathway in the pathogenesis of SLE. On the other hand, contribution of the IFN pathway to anti-neutrophil cytoplasmic antibodies (ANCA) – associated vasculitis (AAV) has not been established. We previously reported association of a single nucleotide polymorphism in interferon regulatory factor 5 (IRF5) gene with susceptibility to myeloperoxidase (MPO)-ANCA-positive AAV in a Japanese population, suggesting a potential role of the IFN pathway in AAV. In the present study, we conducted a transcriptome analysis to examine the contribution of the IFN pathway to AAV and compared the results with those of SLE.

Methods:  Total RNA was extracted from the whole blood of Japanese individuals including 6 patients with microscopic polyangiitis (MPA), 8 patients with SLE and 14 healthy controls using the PAXgene kit. The mRNA levels of the IFN signature genes, previously reported to be differentially expressed in SLE, were analyzed using the Agilent SurePrint G3 Human GE microarray. P values were calculated by Welch’s t-test, and Benjamini-Hochberg false discovery rate (FDR) correction was applied for multiple testing.

Results: In MPA, 68 (17.3%) among the 392 probes for the IFN signature genes were upregulated (PFDR<0.05 and fold change [FC] ≥1.5), showing significant enrichment when compared with 1515 (7.6%) upregulated probes among the 20053 probes in total (Fisher’s exact test P value=9.8E-11). In SLE, 159 out of 392 IFN signature probes (40.6%) were upregulated. Of particular interest, although upregulation of IFN signature gene probes was observed both in SLE and MPA, the sets of upregulated genes showed substantial difference. Cluster analysis showed differential expression patterns in IFN signature genes between MPA and SLE. Principal component analysis using the IFN signature probes confirmed distinct MPA and SLE clusters. When the expression levels of each probe was compared between SLE and MPA, 3228 (16.1%) probes were upregulated in SLE compared with MPA. Among such differentially expressed genes, IFN signature genes showed significant enrichment (115 out of 392 genes, 29.3%, P=3.4E-11).

Conclusion: Although IFN signature was observed also in the peripheral blood of MPA, a substantial proportion of IFN signature genes were differentially expressed between MPA and SLE.


Disclosure: A. Kawasaki, None; D. Tsukui, None; Y. Kondo, None; Y. Kimura, None; K. Asako, None; H. Furukawa, Bristol-Myers Squibb Co., 2; H. Kono, None; T. Sumida, None; N. Tsuchiya, None.

To cite this abstract in AMA style:

Kawasaki A, Tsukui D, Kondo Y, Kimura Y, Asako K, Furukawa H, Kono H, Sumida T, Tsuchiya N. Interferon Signature Genes Are Differentially Expressed Between Microscopic Polyangiitis and Systemic Lupus Erythematosus Peripheral Blood Transcriptomes [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/interferon-signature-genes-are-differentially-expressed-between-microscopic-polyangiitis-and-systemic-lupus-erythematosus-peripheral-blood-transcriptomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-signature-genes-are-differentially-expressed-between-microscopic-polyangiitis-and-systemic-lupus-erythematosus-peripheral-blood-transcriptomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology